Everolimus Taro

/ Taro International Ltd

Treatment should be initiated and supervised by a physician experienced in the use of anticancer therapies or in the treatment of patients with TSC and therapeutic drug monitoring. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
Please refer to the license holder for further details.

* Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis Complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection.
* Treatment of adult patients with renal angiomyolipoma (AML) when the kidney tumor does not require immediate surgery. This type of tumor is associated with a genetic condition known as TSC.
* Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
* Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.
*Treatment of unresectable, locally advanced or metastatic, well-differentiated (Grade 1 or Grade 2) nonfunctional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease

Hypersensitivity to erlotinib or to any of the excipients.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.